177 related articles for article (PubMed ID: 23287011)
41. TGF-β activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases.
Marafini I; Troncone E; Salvatori S; Monteleone G
Pharmacol Res; 2020 May; 155():104757. PubMed ID: 32194176
[TBL] [Abstract][Full Text] [Related]
42. [Effects of perindopril and valsartan on the expression of TGF beta 1 and TGF beta receptor II mRNA, Smad3 and Smad7 in experimental hepatic fibrotic rats].
Gong ZJ; Song SL; Huang YQ; Ruan P
Zhonghua Gan Zang Bing Za Zhi; 2004 Dec; 12(12):737-40. PubMed ID: 15619341
[TBL] [Abstract][Full Text] [Related]
43. Angiotensin II promotes the proliferation of activated pancreatic stellate cells by Smad7 induction through a protein kinase C pathway.
Hama K; Ohnishi H; Aoki H; Kita H; Yamamoto H; Osawa H; Sato K; Tamada K; Mashima H; Yasuda H; Sugano K
Biochem Biophys Res Commun; 2006 Feb; 340(3):742-50. PubMed ID: 16380081
[TBL] [Abstract][Full Text] [Related]
44. Smad7 gene therapy ameliorates an autoimmune crescentic glomerulonephritis in mice.
Ka SM; Huang XR; Lan HY; Tsai PY; Yang SM; Shui HA; Chen A
J Am Soc Nephrol; 2007 Jun; 18(6):1777-88. PubMed ID: 17475816
[TBL] [Abstract][Full Text] [Related]
45. TGF-beta/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation.
Fiocchi C
J Clin Invest; 2001 Aug; 108(4):523-6. PubMed ID: 11518725
[No Abstract] [Full Text] [Related]
46. Smad3 loss confers resistance to the development of trinitrobenzene sulfonic acid-induced colorectal fibrosis.
Latella G; Vetuschi A; Sferra R; Zanninelli G; D'Angelo A; Catitti V; Caprilli R; Flanders KC; Gaudio E
Eur J Clin Invest; 2009 Feb; 39(2):145-56. PubMed ID: 19200168
[TBL] [Abstract][Full Text] [Related]
47. Smad7-modified alleles by various gene-targeting strategies.
Beppu H
J Biochem; 2013 May; 153(5):399-401. PubMed ID: 23509008
[TBL] [Abstract][Full Text] [Related]
48. Ultraviolet A1 phototherapy decreases inhibitory SMAD7 gene expression in localized scleroderma.
Kreuter A; Hyun J; Skrygan M; Sommer A; Tomi NS; Breuckmann F; Altmeyer P; Gambichler T
Arch Dermatol Res; 2006 Nov; 298(6):265-72. PubMed ID: 17009056
[TBL] [Abstract][Full Text] [Related]
49. Targets for new immunomodulation strategies in inflammatory bowel disease.
Monteleone G; Caruso R; Pallone F
Autoimmun Rev; 2014 Jan; 13(1):11-4. PubMed ID: 23774108
[TBL] [Abstract][Full Text] [Related]
50. Smad7 blocks transforming growth factor-β1-induced gingival fibroblast-myofibroblast transition via inhibitory regulation of Smad2 and connective tissue growth factor.
Sobral LM; Montan PF; Zecchin KG; Martelli-Junior H; Vargas PA; Graner E; Coletta RD
J Periodontol; 2011 Apr; 82(4):642-51. PubMed ID: 21054221
[TBL] [Abstract][Full Text] [Related]
51. Reprogramming the immune system in IBD.
MacDonald TT; Vossenkaemper A; Fantini M; Monteleone G
Dig Dis; 2012; 30(4):392-5. PubMed ID: 22796803
[TBL] [Abstract][Full Text] [Related]
52. Effects of perindopril and valsartan on expression of transforming growth factor-beta-Smads in experimental hepatic fibrosis in rats.
Xu W; Song S; Huang Y; Gong Z
J Gastroenterol Hepatol; 2006 Aug; 21(8):1250-6. PubMed ID: 16872305
[TBL] [Abstract][Full Text] [Related]
53. Interleukin-25 production is differently regulated by TNF-α and TGF-β1 in the human gut.
Fina D; Franzè E; Rovedatti L; Corazza GR; Biancone L; Sileri PP; Sica G; MacDonald TT; Pallone F; Di Sabatino A; Monteleone G
Mucosal Immunol; 2011 Mar; 4(2):239-44. PubMed ID: 20944558
[TBL] [Abstract][Full Text] [Related]
54. Smad7 antagonizes transforming growth factor beta signaling in the nucleus by interfering with functional Smad-DNA complex formation.
Zhang S; Fei T; Zhang L; Zhang R; Chen F; Ning Y; Han Y; Feng XH; Meng A; Chen YG
Mol Cell Biol; 2007 Jun; 27(12):4488-99. PubMed ID: 17438144
[TBL] [Abstract][Full Text] [Related]
55. Inhibitory role of Smad7 in hepatocarcinogenesis in mice and in vitro.
Wang J; Zhao J; Chu ES; Mok MT; Go MY; Man K; Heuchel R; Lan HY; Chang Z; Sung JJ; Yu J
J Pathol; 2013 Aug; 230(4):441-52. PubMed ID: 23625826
[TBL] [Abstract][Full Text] [Related]
56. Boswellia serrata and Salvia miltiorrhiza extracts reduce DMN-induced hepatic fibrosis in mice by TGF-beta1 downregulation.
Sferra R; Vetuschi A; Catitti V; Ammanniti S; Pompili S; Melideo D; Frieri G; Gaudio E; Latella G
Eur Rev Med Pharmacol Sci; 2012 Oct; 16(11):1484-98. PubMed ID: 23111960
[TBL] [Abstract][Full Text] [Related]
57. [Present states of development in new drugs and treatment of inflammatory bowel disease].
Asakura H; Sugimura K
Nihon Rinsho; 1999 Nov; 57(11):2490-5. PubMed ID: 10572418
[TBL] [Abstract][Full Text] [Related]
58. Effects of RNA interference targeting transforming growth factor-beta 1 on immune hepatic fibrosis induced by Concanavalin A in mice.
Xu W; Wang LW; Shi JZ; Gong ZJ
Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):300-8. PubMed ID: 19502172
[TBL] [Abstract][Full Text] [Related]
59. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer.
Kleeff J; Ishiwata T; Maruyama H; Friess H; Truong P; Büchler MW; Falb D; Korc M
Oncogene; 1999 Sep; 18(39):5363-72. PubMed ID: 10498890
[TBL] [Abstract][Full Text] [Related]
60. Transforming growth factor-beta1 and activin A generate antiproliferative signaling in thyroid cancer cells.
Matsuo SE; Leoni SG; Colquhoun A; Kimura ET
J Endocrinol; 2006 Jul; 190(1):141-50. PubMed ID: 16837618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
